TNP 2092

Drug Profile

TNP 2092

Alternative Names: CBR-2092

Latest Information Update: 14 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cumbre Pharmaceuticals
  • Developer Cumbre Pharmaceuticals; TenNor Therapeutics
  • Class Antibacterials; Quinolizines; Rifamycins
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase inhibitors; DNA topoisomerase IV inhibitors; DNA-directed RNA polymerase inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Bacterial infections

Most Recent Events

  • 27 Jun 2016 TenNor Therapeutics initiates a clinical trial for Bacterial infections, including prosthetic joint infections (PO)
  • 27 Jun 2016 Clinical trials in Bacterial infections in China (PO) before June 2016
  • 16 Jun 2016 Antimicrobial data from preclinical studies in Bacterial infections presented at the ASM Microbe 2016 (ASMM-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top